The new pen injector's small size is complemented by a flexible design with adjustable dosing and push-button colours to signify various dosing and drug needs for a variety of therapies
Phillips-Medisize expand its product portfolio with new disposable pen injector. (Credit: Molex)
Phillips-Medisize, a division of consumer electronics provider Molex, has launched a new disposable pen injector to expand its product portfolio.
The Wisconsin-based diagnostic device maker has created the new injector for high-volume production. It aims to offer pharmaceutical companies a pen injector to enable a quicker, more effective, and cost-effective entry into the markets.
According to Phillips-Medisize, the product is designed for matching user expectations and experiences with familiar disposable pen products but is markedly smaller than a majority of comparable products in the market.
The new pen injector’s small size is complemented by a flexible design with adjustable dosing and push-button colours to signify various dosing and drug requirements for a variety of therapies, Phillips-Medisize said.
The diagnostic device maker said that the disposable pen injector aims to assist drug delivery businesses to meet expanding pen injector market while lowering costs and risks associated with commercialisation.
Molex senior vice president and medical and pharmaceutical solutions president Paul Chaffin said: “A Pen Injector is an important addition to Phillips-Medisize’s expanding Product and Platform portfolio that empowers Biopharma companies to accelerate the rollout of novel and generic drug treatments at significant economies of scale.
“This ‘ready-to-go’ solution offers all of the advantages expected from ‘state of the art’ pen designs, while benefiting from our decades of device development and large-volume manufacturing expertise to reduce the challenges of bringing affordable drugs and drug-delivery devices to market.”
The pen injector joins the firm’s Aria Smart Autoinjector, which debuted in May 2021.
Phillips-Medisize said that by launching the pen injector, it can offer increased choice to biopharma firms across the two large injector market segments.